Minnesota's health department is not going to add anxiety as a condition to require medical marijuana claiming that there is not enough research to prove the benefits of the situation weighed against the negative sides. Jan Malcolm, the health commissioner of the state said that "We recognize that not everyone has equal access to therapy - which is considered the front-line treatment - but ultimately we concluded that the risk of additional harms to patients outweighed perceived benefits." The Minnesota health department added that the state will not add any new conditions to the existing 17 conditions that can officially require medical cannabis. "We received many comments from health care practitioners treating patients with anxiety disorder, and they urged us to not approve it as a qualifying medical condition," Malcolm said. Anxiety has been one of the most cited conditions for prescription cannabis in the US for the last few years and states like North Dakota have already added the condition to the list. The state said that the petitioners have rallied to add anxiety to the list since 2016 but a continued lack of medical evidence. Minnesota has added a few different ways of delivering edibles like in the form of gummies and chews. The list already approved pills, vapor oil, powdered mix, liquids, and lozenge-like dissolvable medicines. "Expanding delivery methods to gummies and chews will mean more options for patients who cannot tolerate currently available forms of medical cannabis,"Malcolm added. The new delivery methods will be effective from August 1, 2022
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.